Financial Results for quarter and nine months ended December 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shree Ganesh Remedies reported Q3 FY26 standalone revenue of Rs 2,110.68 lakhs, down 22% from Rs 2,705.28 lakhs in Q3 FY25. Profit after tax fell to Rs 309.62 lakhs from Rs 543.34 lakhs, a drop of about 43% year-on-year. For the nine months ended December 2025, revenue declined around 9.6% to Rs 7,608.96 lakhs and PAT fell 30% to Rs 1,150.11 lakhs. Sequentially, Q3 results also weakened sharply compared to Q2 FY26 (revenue was Rs 3,031.50 lakhs and PAT Rs 495.57 lakhs), indicating margin pressure as costs stayed high. Consolidated results were broadly in line with standalone figures; the wholly owned US subsidiary SGRL USA INC contributed nil revenue and a small loss of Rs 0.95 lakhs. The auditor (Chaudhary Shah & Associates LLP) issued a clean limited review report with no qualifications.
Shareholders should note a significant slowdown in both top line and profitability, with profits falling much faster than sales, suggesting margin compression. This weak print may weigh on near-term stock sentiment, though the auditor's clean report offers some comfort on reporting quality.